Quarterly report · Q1
9987.TEDINET S100OZ8T
Period2022-04-01 → 2022-06-30
Filed2022-08-12
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥553.8bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Revenue | ¥2.24T | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥541.1bn | 2021-04-01 → 2021-06-30 | Cons. | Net sales |
| Operating income | ¥3.5bn | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Operating income | −¥1.6bn | 2021-04-01 → 2021-06-30 | Cons. | Operating income |
| Ordinary income | ¥4.6bn | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥23.4bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥443m | 2021-04-01 → 2021-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥4.5bn | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Profit before tax | −¥479m | 2021-04-01 → 2021-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.7bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥14.4bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥414m | 2021-04-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.7bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Net income | −¥373m | 2021-04-01 → 2021-06-30 | Cons. | Profit loss |
| Total assets | ¥1.17T | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥1.14T | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥1.17T | at 2021-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥745.8bn | at 2022-06-30 | Cons. | Liabilities |
| Total liabilities | ¥723.7bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥419.3bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥418.1bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥415.3bn | at 2021-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥132.1bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥141.4bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥30.49 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥163.19 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-4.66 | 2021-04-01 → 2021-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 36.0% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.4% | at 2021-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 40
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥52.6bn |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥9.8bn |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥42.8bn |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥434m |
| jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥21.4bn |
| jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥21.4bn |
| jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥1m |
| jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥31m |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥533.5bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥519.6bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥13.8bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥2.4bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥11.5bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥2.9bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥8.6bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥587m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-06-30 | ¥618.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-06-30 | ¥553.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥65.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-06-30 | ¥3.5bn |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥41.9bn |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥9.8bn |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥32.1bn |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥644m |
| jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥21.9bn |
| jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥21.9bn |
| jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥5m |
| jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥323m |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥520.1bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥506.1bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥13.9bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | segment profit | 2021-04-01 → 2021-06-30 | −¥3.2bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥11.3bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥3.3bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥7.9bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥468m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-06-30 | ¥595.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-06-30 | ¥541.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥54.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-06-30 | −¥1.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 350
| Item | Context | Value | Unit |
|---|---|---|---|
| Profit loss | CurrentYTDDuration | 2674000000 | JPY |
| Valuation difference on available for sale securities net of tax oci | Prior1YTDDuration | 4456000000 | JPY |
| Valuation difference on available for sale securities net of tax oci | CurrentYTDDuration | 1343000000 | JPY |
| Foreign currency translation adjustment net of tax oci | Prior1YTDDuration | 20000000 | JPY |
| Foreign currency translation adjustment net of tax oci | CurrentYTDDuration | 18000000 | JPY |
| Remeasurements of defined benefit plans net of tax oci | Prior1YTDDuration | -64000000 | JPY |
| Remeasurements of defined benefit plans net of tax oci | CurrentYTDDuration | -136000000 | JPY |
| Share of other comprehensive income of associates accounted for using equity method oci | Prior1YTDDuration | 256000000 | JPY |
| Share of other comprehensive income of associates accounted for using equity method oci | CurrentYTDDuration | 500000000 | JPY |
| Other comprehensive income | Prior1YTDDuration | 4669000000 | JPY |
| Other comprehensive income | CurrentYTDDuration | 1725000000 | JPY |
| Comprehensive income | Prior1YTDDuration | 4296000000 | JPY |
| Comprehensive income | CurrentYTDDuration | 4400000000 | JPY |
| Comprehensive income attributable to owners of the parent | Prior1YTDDuration | 4243000000 | JPY |
| Comprehensive income attributable to owners of the parent | CurrentYTDDuration | 4407000000 | JPY |
| Comprehensive income attributable to non controlling interests | Prior1YTDDuration | 52000000 | JPY |
| Comprehensive income attributable to non controlling interests | CurrentYTDDuration | -6000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 506145000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E02780-000ThePharmaceuticalManufacturingBusinessReportableSegmentsMember | 3338000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E02780-000TheInsurancePharmacyBusinessReportableSegmentsMember | 21858000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | 9759000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 541102000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 13911000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E02780-000ThePharmaceuticalManufacturingBusinessReportableSegmentsMember | 7947000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E02780-000TheInsurancePharmacyBusinessReportableSegmentsMember | 5000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | 32150000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 54014000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 520056000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E02780-000ThePharmaceuticalManufacturingBusinessReportableSegmentsMember | 11286000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E02780-000TheInsurancePharmacyBusinessReportableSegmentsMember | 21864000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | 41909000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 595117000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | -3176000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E02780-000ThePharmaceuticalManufacturingBusinessReportableSegmentsMember | 468000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E02780-000TheInsurancePharmacyBusinessReportableSegmentsMember | 323000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | 644000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | -1739000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 519633000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E02780-000ThePharmaceuticalManufacturingBusinessReportableSegmentsMember | 2903000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E02780-000TheInsurancePharmacyBusinessReportableSegmentsMember | 21446000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | 9770000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 553754000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 13820000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E02780-000ThePharmaceuticalManufacturingBusinessReportableSegmentsMember | 8563000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E02780-000TheInsurancePharmacyBusinessReportableSegmentsMember | 1000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | 42786000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 65171000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 533454000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E02780-000ThePharmaceuticalManufacturingBusinessReportableSegmentsMember | 11467000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E02780-000TheInsurancePharmacyBusinessReportableSegmentsMember | 21447000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |